Prothena Corporation plc (NASDAQ:PRTA) Analyst Ratings as of May 17, 2018

May 17, 2018 - By Kyle Williams

Prothena Corporation plc (NASDAQ:PRTA) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.18. That’s change of 0.47, from 2017Q3’s 1.65. 29 investors sold all, 32 reduced holdings as Prothena Corporation plc ratio dived. 44 rose holdings while 28 funds bought holdings. Funds hold 31.32 million shares thus 0.27% more from 2017Q3’s 31.24 million shares.
Rhumbline Advisers invested in 0% or 38,513 shs. Citadel Advsrs Limited Liability Com owns 66,868 shs. Stratos Wealth Prtn Limited accumulated 9 shs. Ubs Asset Americas reported 48 shs. Rock Springs Capital Management L P reported 310,000 shs. Granite Point Cap Mngmt Lp reported 0.11% stake. Hood River Capital Mgmt Lc owns 0.46% invested in Prothena Corporation plc (NASDAQ:PRTA) for 213,119 shs. Jpmorgan Chase And holds 0% or 104,285 shs in its capital. Envestnet Asset Management owns 108 shs or 0% of their US capital. Pnc Svcs Grp Inc Incorporated stated it has 5,384 shs or 0% of all its holdings. Aqr Ltd Llc invested 0% of its capital in Prothena Corporation plc (NASDAQ:PRTA). Bancorp Of America De holds 14,055 shs or 0% of its capital. State Of Wisconsin Investment Board reported 0% of its capital in Prothena Corporation plc (NASDAQ:PRTA). Washington Commercial Bank reported 6 shs. Meeder Asset Mgmt reported 108 shs or 0% of all its holdings.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

In total 10 analysts cover Prothena Corp PLC (NASDAQ:PRTA). “Buy” rating has 3, “Sell” are 0, while 7 are “Hold”. (NASDAQ:PRTA) has 30% bullish analysts. 16 are the (NASDAQ:PRTA)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. In Wednesday, December 20 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Thursday, April 5 the company was maintained by Barclays Capital. On Monday, April 23 the company was downgraded by Jefferies. On Tuesday, April 24 BTIG Research downgraded the shares of PRTA in report to “Neutral” rating. On Monday, November 20 the stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Neutral” rating by Wedbush. In Thursday, February 15 report Cantor Fitzgerald maintained it with “Buy” rating and $65.0 target. On Tuesday, April 24 the rating was maintained by Nomura with “Buy”. The company rating was downgraded by Evercore on Monday, April 23. On Monday, April 23 the stock of Prothena Corporation plc (NASDAQ:PRTA) has “Hold” rating given by RBC Capital Markets. On Monday, April 23 the stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Hold” rating by Barclays Capital. Listed here are Prothena Corporation plc (NASDAQ:PRTA) PTs and latest ratings.

24/04/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $87 New Target: $19 Maintain
24/04/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $78 New Target: $16 Maintain
24/04/2018 Broker: BTIG Research Old Rating: Buy New Rating: Neutral Old Target: $77 Downgrade
24/04/2018 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $14 Maintain
23/04/2018 Broker: Oppenheimer Rating: Hold Downgrade
23/04/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
23/04/2018 Broker: Barclays Capital Rating: Hold Downgrade
23/04/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Old Target: $100 Downgrade
23/04/2018 Broker: Evercore Old Rating: Outperform New Rating: In-Line Old Target: $76 New Target: $12 Downgrade
05/04/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $70 New Target: $50 Maintain

PRTA touched $16.31 during the last trading session after $0.12 change.Currently Prothena Corporation plc is downtrending after 31.00% change in last May 17, 2017. PRTA has also 378,815 shares volume. PRTA underperformed by 42.55% the S&P 500.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion.The firm is worth $649.50 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating ParkinsonÂ’s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development.Currently it has negative earnings. The firm has a license, development, and commercialization agreement with F.

For more Prothena Corporation plc (NASDAQ:PRTA) news released briefly go to: Digitaljournal.com, Globenewswire.com, Nasdaq.com, Seekingalpha.com or Prnewswire.com. The titles are as follows: “NASDAQ:PRTA Shareholder Notice: Investigation over Possible Violations of Securities Laws by Prothena Corporation …” released on May 08, 2018, “Prothena to Report First Quarter 2018 Financial Results on May 8” on May 01, 2018, “Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update” with a publish date: May 08, 2018, “Prothena: What Now?” and the last “PROTHENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 …” with publication date: May 16, 2018.

Prothena Corporation plc (NASDAQ:PRTA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.